RecruitingPhase 2NCT06895928

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

A Phase II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrollment

400 participants

Start Date

Mar 28, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Adebelimab Injection, a drug called Ametinib Mesylate Tablets, and others for people with advanced solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.